Apyx Medical Corporation (APYX) Q2 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
Despite a year-over-year revenue decline, the company demonstrated improved cost management, reducing losses significantly. The AYON product launch has been well-received, with strong presales and positive feedback, leading to raised guidance. The addition of experienced commercial hires and a promising partnership in China further bolster growth prospects. Although financial results were mixed, the optimistic guidance and strategic moves suggest a positive stock price movement over the next two weeks.
Key Financial Performance
Total Revenue $11.4 million, a 6% decrease year-over-year from $12.1 million. The decline was primarily driven by a decrease in sales of OEM products, aligning with the company's strategic shift in focus and resource allocation.
Advanced Energy Product Sales $9.7 million, relatively flat compared to $9.8 million last year. The flattening was due to a decrease in the volume of single-use handpieces sold domestically, attributed to a decline in overall procedures and a strategic focus on presales of the AYON system.
OEM Segment Sales Decreased by 29% or approximately $1.7 million year-over-year. The decline was due to reduced sales volume to existing customers, including Symmetry Surgical under a 10-year generator manufacturing and supply agreement.
Domestic Revenue Decreased by 11% year-over-year to $7.8 million. The decline reflects the overall decrease in sales volume and strategic shifts.
International Revenue Decreased by 4% year-over-year to $3.6 million. The decline reflects the overall decrease in sales volume and strategic shifts.
Gross Profit $7.1 million, a decrease from $7.5 million in the prior year period. Gross profit margin slightly increased to 62.3% from 61.7%.
Operating Expenses Decreased to $9.7 million from $13 million in the prior year period. The reduction was driven by decreases in salaries and related costs ($1.6 million), selling, general and administrative expenses ($0.7 million), research and development expenses ($0.6 million), and professional services expenses ($0.5 million).
Loss from Operations Decreased by $3 million or 54% to $2.6 million year-over-year. This reflects the impact of cost-cutting measures implemented in late 2024.
Net Loss Attributable to Stockholders $3.8 million or $0.09 per share, compared to $6.6 million or $0.19 per share in the prior year period. The improvement reflects reduced operating expenses and cost management.
Adjusted EBITDA Loss Decreased by 54% to $2 million compared to $4.3 million in the prior year period. This reflects improved cost management and operational efficiency.
Cash Used in Operating Activities Decreased to $1.2 million from $4.3 million in the prior year period. This improvement reflects better cash and working capital management.
Cash and Cash Equivalents $29.3 million as of June 30, 2025, compared to $31.7 million as of December 31, 2024. The decrease reflects cash burn related to operations and the AYON launch.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
AYON System: The AYON system, an all-in-one platform integrating Renuvion, ultrasound-assisted liposuction, infiltration, aspiration, electrocoagulation, and fat transfer, has been introduced. It has received FDA 510(k) clearance and is in a soft commercial launch phase. Early results from presales have exceeded expectations, and the broader commercial rollout is planned for September 2025.
Renuvion: Renuvion, a minimally invasive surgical solution for skin tightening, is gaining traction among surgeons and is being positioned as a new standard of care for patients with skin laxity, including those using GLP-1 medications. It has been launched in China with strong initial success.
China Market Expansion: Renuvion has been launched in China following market clearance from the National Medical Products Administration. A distribution agreement with GlamMoon Medical Technology has been established, and initial sales have been promising.
Cost Reduction and Restructuring: Cost reduction and restructuring initiatives implemented in November 2024 have resulted in a leaner operating structure, significant cash burn reduction, and improved financial health.
Leadership Appointments: Two senior sales leaders have been appointed: John Featherstone for North America and Simon Davies for Europe and Asia, both bringing extensive experience in the aesthetics industry.
Strategic Shift in Focus: The company is shifting focus and resources towards Advanced Energy products, particularly the AYON system and Renuvion, while reducing emphasis on OEM products.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Revenue Decline: Total revenue decreased by 6% year-over-year in Q2 2025, primarily due to a 29% drop in OEM sales and a slight decline in Advanced Energy product sales. This decline could impact the company's financial stability and growth trajectory.
Market Challenges: The global aesthetic market remains challenging, with subdued capital equipment spending across the industry. This could hinder the adoption of new products like AYON.
Supply Chain and Tariff Risks: Uncertainty around tariffs and trade policies could impact the cost structure and profitability of the company.
Operational Costs: While cost-cutting measures have been implemented, operating expenses remain significant, and any inefficiencies could strain financial resources.
Product Launch Risks: The success of the AYON system is critical to future growth, but its adoption depends on market reception and the ability to scale production and distribution effectively.
Economic Uncertainty: Economic factors, including seasonality and shifts in consumer spending, could affect revenue and operational performance.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Guidance for 2025: Total revenue is expected to range between $50 million and $52 million, up from the previous guidance of $47.6 million to $49 million. This represents an increase from $48.1 million in 2024.
Advanced Energy Revenue: Revenue is projected to range between $42 million and $44 million, up from the previous guidance of $39.6 million to $41 million. This is an increase from $38.6 million in 2024.
OEM Revenue: Revenue is expected to be approximately $8 million, compared to $9.5 million in 2024.
Gross Margins: Gross margins are anticipated to remain at approximately 60% for the year.
Operating Expenses: Total operating expenses are not expected to exceed $40 million for 2025.
AYON System Launch: The AYON system is expected to drive significant growth, with a broader commercial rollout planned for September 2025. Early interest and preorders have exceeded expectations, indicating strong market demand.
Market Trends and Growth Drivers: The adoption of GLP-1 drugs is creating a new patient population with skin laxity, presenting a significant growth opportunity for the Renuvion system. The company is well-positioned to capitalize on this trend.
International Expansion: Renuvion has been launched in China, with early success reported. The company anticipates this market to be a key growth driver.
Capital Equipment Spending: The AYON system is expected to reverse the subdued capital equipment spending trend in the aesthetics market, with strong enthusiasm from surgeons.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:How should we think about customer receptivity to AYON in the current market environment?
A:Charles D. Goodwin stated that the reaction from doctors has been spectacular since the launch of AYON. The system was designed by surgeons for surgeons, meeting their needs effectively. Despite the challenging market environment, the presales and positive feedback have been strong, leading to raised guidance.
Q:How do the new commercial hires position the company to take advantage of the current opportunities?
A:Charles D. Goodwin expressed enthusiasm about the new hires, John Featherstone and Simon Davies, highlighting their extensive experience. Featherstone brings over 20 years of expertise, while Davies has significant knowledge in body contouring. Their addition is expected to drive the adoption of AYON and Renuvion globally.
Q:What are the expectations regarding seasonality and the impact of AYON's launch on Q3 and Q4 performance?
A:Matthew C. Hill explained that while there is typically a dip from Q2 to Q3, the commercial launch of AYON in September might alter this pattern. A strong Q4 is anticipated as most AYON shipments are scheduled for October through December.
Q:What is the market opportunity in China, and why is GlamMoon the right partner for Renuvion?
A:Charles D. Goodwin described China as a significant opportunity with about 5,000 plastic surgeons and a growing middle-to-upper class. GlamMoon, the chosen partner, owns numerous aesthetic facilities in China, providing immediate access to the market and potential for expansion. The partnership is in its early stages but is expected to drive revenue for years.
Q:Review of Unclear Management Responses
A:No questions were identified where management avoided giving a direct answer or lacked clarity in their responses.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
AYON clearance
AYON month
AYON preparation
AYON presales
AYON sale
AYON system
Administration China
Advisors LLC
Advisors reference
Asia year
BTIG LLC
Feffer
GlamMoon
Miami
aesthetic industry
aesthetic market
ambassador program
care
center
confidence
decline
demand
distribution
focus
launch
leader
moment
momentum
platform
process
reach
rollout
shift market
stage
success
value
year experience
APYX Transcript
Apyx Medical Corporation (APYX) Q1 2026 Earnings Call Transcript
Positive5-7
The earnings call shows strong financial performance with significant revenue growth, improved margins, and reduced losses. The AYON platform's successful launch and international expansion plans further enhance prospects. Although management's lack of specificity on international timelines adds uncertainty, the overall sentiment remains positive due to strong domestic growth and strategic focus on high-demand segments. The positive outlook is bolstered by the company's robust cash position and cost management.
Apyx Medical Corporation (APYX) Q4 2025 Earnings Call Transcript
Positive3-10
The earnings call reveals strong financial performance with increased revenues, improved EBITDA, and reduced net loss. The AYON platform's successful launch and positive feedback, along with optimistic guidance and growth strategies, contribute to a favorable outlook. Despite some conservative guidance and management's avoidance of specifics, the overall sentiment, including potential upside from liposuction expansion, indicates a positive stock price reaction.
Apyx Medical Corporation (APYX) Q3 2025 Earnings Call Transcript
Positive11-6
The earnings call highlights a positive outlook with increased revenue guidance and improved financial metrics, such as higher gross margins and reduced net loss. The AYON system launch and international expansion are expected to drive growth. Despite some vague management responses in the Q&A, the overall sentiment is boosted by strong demand and strategic initiatives, leading to a positive stock price prediction.
Apyx Medical Corporation (APYX) Q2 2025 Earnings Call Transcript
Positive8-8
Despite a year-over-year revenue decline, the company demonstrated improved cost management, reducing losses significantly. The AYON product launch has been well-received, with strong presales and positive feedback, leading to raised guidance. The addition of experienced commercial hires and a promising partnership in China further bolster growth prospects. Although financial results were mixed, the optimistic guidance and strategic moves suggest a positive stock price movement over the next two weeks.
APYX Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
